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Abstract: Intense research in the areas of cellular 
and organismal aging using diverse laboratory model 
systems has enriched our knowledge in the processes 
and the signalling pathways involved in normal and 
pathological conditions. The field finds itself in a position 
to take decisive steps towards clinical applications and 
interventions not only for targeted age-related diseases 
such as cardiovascular conditions and neurodegeneration 
but also for the modulation of health span and lifespan of 
a whole organism. Beyond nutritional interventions such 
as dietary restriction without malnutrition and various 
regimes of intermittent fasting, accumulating evidence 
provides promise for pharmacological interventions. The 
latter, mimic caloric or dietary restriction, tune cellular 
and organismal stress responses, affect the metabolism 
of microbiome with subsequent effects on the host or 
modulate repair pathways, among others. In this mini 
review, we summarise some of the evidence on drugs 
that can alter organismal lifespan and the prospects they 
might offer for promoting healthspan and delaying age-
related diseases.
Keywords: TOR; rapamycin; rapalogs; Torin; metformin; 
insulin growth signalling pathway; aspirin; lifespan.
Introduction
Human life expectancies are steadily rising worldwide, 
with the demographics of developed countries being 
shifted towards older ages [1]. This change is accompanied 
by a disturbing price tag: an increase in occurrence of 
age-related diseases together with personal, social and 
financial burdens [2] with 40% of the National Health 
System’s budget spent on over 65s in the UK. Aging 
research and biogerontology has long been concentrated 
on the molecular workings underlying the aging 
phenomenon towards increasing the healthspan and 
extending the productive timeframes of an individual. 
Based on various theories of aging [3-6], scientists have 
focused efforts on processes, genetic, epigenetic or 
environmental factors that could be setting the pace of the 
biological clock; or alternatively those that are potentially 
direct targets, mediators or effectors of this clock. For 
example, the understanding of the role of nutrition and 
evolutionarily conserved nutrient-responsive pathways, 
such as the Insulin Growth Factor (IGF) or the Target 
of rapamycin (TOR) [7], has been pivotal in linking 
metabolism, bioenergetics and lifespan. Dissection 
of these pathways has led us to comprehend genetic 
perturbations that prolong lifespan, and has provided a 
picture of the molecular players and functional networks 
towards developing pharmacological interventions for 
modulation of stress responses and amelioration or even 
prevention of age-related diseases. In this mini review we 
will briefly discuss some of these drugs that clearly extend 
lifespan or reduce aging rates in diverse model systems. 
We will refer to signalling pathways such as TOR, AMP-
activated protein kinase (AMPK) and IGF. We will also 
discuss compounds such as metformin or aspirin that are 
widely used in pathologies as well as dietary supplements 
such as resveratrol. The effects of these drugs on aging 
and lifespan are without a doubt impressive based on 
laboratory model systems data. Although some of them 
are prescribed for treating diseases (such as metformin 
for diabetes) their ability to modulate accordingly human 
aging rates, lifespan and more importantly, healthspan 
still remains to be demonstrated.  
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Rapamycin, rapalogs and ATP-
analogues: inhibiting the TOR 
signaling pathway
First isolated from the bacteria Streptomyces hygroscopicus 
by Suren Sehgal in 1972, and identified as an antifungal 
[8], the macrolide rapamycin has been the subject of 
research interest for nearly 50 years. Initially, rapamycin 
showed immunosuppressive potential and gained FDA 
approval for this purpose [9]. It has since been found to 
be the first pharmacological agent to extend lifespan in 
both genders of a mammalian species [10]. As its name 
suggests, rapamycin works by inhibition of the Target 
of Rapamycin (TOR) pathway which is an evolutionarily 
conserved nutrient-responsive pathway serving as a 
cellular rheostat of energy and a regulator of metabolism 
and growth [11]. 
Initial discovery of the TOR pathway came in the 
early 1990s (much later than the discovery of rapamycin) 
by several methods. Firstly, a genetic screen for 
Saccharomyces cerevisiae mutants identified the gene 
encoding the cellular receptor for rapamycin, FKBP (FPR1) 
[12] after the same team had previously identified FKBP as 
the binding protein for rapamycin’s structural homologue 
FK-506 [13]. While the genes were identified in Heitman’s 
screen, TOR1 and TOR2, the two TOR kinase homologues 
more commonly referred to as the targets of Rapamycin, 
were not fully characterised until 1993 and 1994 when 
TOR2 was identified as a target of rapamycin [14] and 
TOR1/2 were found to be structurally and functionally 
similar but non-identical [15].
The importance of these characterisations can only be 
fully appreciated when viewed within the context of the 
conservation of TOR from yeast to man. In humans, there 
is one TOR kinase, known as mechanistic TOR or mTOR 
[11], rather than the two homologues found in yeast [16]. 
The isolation of mTOR came in 1994 and marked the first 
evidence that yeast could be used as a relevant model 
organism for TOR-related research in humans. mTOR was 
initially identified as the FKBP-rapamycin-associated-
protein (FRAP) [17] but was referred to as mTOR after 
it was found to be an orthologue to the yeast TOR 
homologues [18]. Intense research established that mTOR, 
Figure 1: Overview of the signaling pathways controlling cellular growth, metabolism and affecting aging, and some of the drugs mentioned 
in the manuscript. A. Relationships between IGF/GH axis, TOR and AMPK pathways and sirtuins in aging and lifespan regulation and drugs 
that either inhibit or boost their functions (look inside text for details). B. General scheme for the inhibitory action of aspirin on COX1 and 
COX2 leading to beneficial cellular and organismal effects. 
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as its yeast orthologues, exists and functions within two 
highly conserved protein complexes termed mTORC1 and 
mTORC2 [9].
TOR1, TOR2 and mTOR are all considered to be 
rapamycin targets (Figure 1A) in their respective 
organisms and, while some key points are known, 
research into the relationship between TOR inhibition 
and aging is still ongoing. However, despite the lack of a 
fully elucidated mechanism, rapamycin and its analogs 
or ‘rapalogs’ have long been considered a key candidate 
for the pharmacological intervention of aging, with strong 
evidence showing that rapamycin increases the lifespan 
and healthspan in mouse models [19-24].  Rapalogs 
hold an advantage over rapamycin itself as a treatment 
option as they can be developed to have more favourable 
pharmacological conditions and provide an opportunity 
for intellectual property, which can be advantageous to 
the drug development industry [25].
The two complexes, mTORC1 and mTORC2, are 
differently affected by rapamycin treatment with mTORC1 
inhibition occurring immediately and mTORC2 inhibition 
occurring only after prolonged treatment with the drug 
[26]. The two mTOR complexes are not only structurally 
different from one another; they also have distinct 
differences in their downstream functions. mTORC1 is 
associated with the control of anabolic and catabolic 
processes in response to nutrient availability [27] and is 
much better understood than mTORC2 but it is believed 
that both could potentially affect healthy lifespan and 
aging. 
Beyond lifespan extension, rapamycin has also 
shown promise in age-related disease intervention. Age-
related diseases pose a threat in much of the developed 
world where longer lives, poorer diets and lifestyles are 
considered to be contributing to the rise in these diseases. 
According to the World Health Organisation there is a 
distinct gap between life expectancy and healthy life 
expectancy across the globe. This is an important point 
to address with pharmacological interventions since the 
goal would be to extend both the lifespan and healthspan 
not just increase lifespan at any cost to life quality.
Inflammation is considered to play an important role 
in many age-related diseases and rapamycin has been 
shown to have anti-inflammatory effects [27] to the extent 
of being used as an immunosuppressive drug [9]. Chronic 
inflammation has been shown to underpin the mechanism 
of a number of age-related diseases including cancer, 
dementia and cardiovascular diseases [28]. Dietary and 
exercise interventions are often advised in these cases 
however there is a potential for rapamycin to add to these 
as a pharmacological option. 
It is not just inflammation-related mechanisms 
that rapamycin has shown promise in such diseases. 
In cancer, rapamycin has been FDA approved for renal 
cell carcinoma, mantle cell lymphoma, and pancreatic 
cancer [27]. It is common to see an upregulation of mTOR 
signalling in cancer patients, creating an interest in 
mTOR inhibition as a treatment option. However, a major 
limitation of using rapamycin or rapalogs in this way is 
that the drugs are often cytostatic rather than cytotoxic 
causing tumour growth to slow or stop but not reducing 
tumour size [25]. 
In Alzheimer’s disease and vascular dementia, 
cerebrovascular dysfunction can be one of the early 
symptoms used to diagnose the disease [29]. It is also 
suggested to be a major contributor to disease onset and 
progression [30]. This highlights the importance of recent 
findings that mTOR could be a target for neuroprotection 
and vasculoprotection via inhibition with rapamycin [29] 
such as the inhibition of mTOR with rapamycin preventing 
ANG II-mediated endothelial vascular dysfunction [31]. 
Unfortunately, the use of rapamycin as a drug 
does not come without side effects. Dyslipidaemia is a 
common and concerning side effect of mTOR inhibition 
and is observed in 40-75% of patients treated with 
rapamycin or rapalogs [32, 33]. Inhibition of mTORC1, 
seen in acute rapamycin treatment, leads to an increase 
in LDL cholesterol levels, hyperlipidaemia, and increased 
lipophagy. Chronic rapamycin treatment promoting 
mTORC2 inhibition also increases lipolysis via an 
unknown mechanism [33]. Interestingly, despite the 
high occurrence of dyslipidaemia, rapamycin treatment 
can be used to combat atherosclerosis, the process by 
which damage to blood vessel walls leads to blockages 
and therefore coronary problems such as stroke and 
heart attack. mTOR inhibition by rapamycin can lead to 
decreased atherosclerosis and potentially even reversal of 
disease progression [32]. The combination of rapamycin or 
rapalogs with stents has also been shown to be successful 
either as a drug eluting stent [34] or as an oral treatment 
alongside a base metal stent [35]. 
Intense research has led to the identification of potent 
ATP-analog mTOR inhibitors. Developed by AstraZeneca, 
the ATP-competitive mTOR inhibitors Torin1 [36] and 
Torin2 [37] can inhibit both mTORC1 and mTORC2 [25] 
(Figure 1A). Torin1 has been used in a few settings to 
demonstrate anti-aging properties. Interestingly, Torin1 
was shown to be more potent than rapamycin in inhibiting 
senescent morphology in human cells, suggesting that 
these processes may rely on rapamycin-insensitive aspects 
of TOR signaling [38, 39]. Torin1-fed fruit flies exhibited 
increased lifespan without reduced fertility [40]. Regarding 
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treatment of age-related diseases with ATP-competitive 
TOR inhibitors there is currently limited data available. 
Nevertheless, Torin1 has no additional beneficial effects 
in cancer treatment compared to rapamycin: strong 
pan-TOR inhibition causes severe cell growth arrest and 
inhibition of pivotal cellular processes within all, healthy 
or not cells [25, 41]. Having only been synthesised in 2009, 
research into the effects of Torin1 and 2 on aging and age-
related diseases is still in its early steps. The potency and 
selectivity of their action encourage further analysis of 
how they could be utilised in aging and pathologies.
Resveratrol
In the context of biogerontology, resveratrol is one of the 
most widely studied molecules [42] due its notable ability 
to counteract different age-related diseases in mammals 
with apparent lack of toxicity [43]. This polyphenolic 
natural product is not recommended during pregnancy, 
even though it is not toxic for animals [44]. It was 
initially described in 1939 in ethanol extracts of the white 
hellebore Veratrum grandiflorum and firstly characterized 
as a phytoalexin [42]. In recent years, it has been shown 
to be present in grapes, red wine and a few other species 
under stress conditions [45]. 
There are two isomeric configurations of this 
compound (3,5,4’-trihydroxystilbene) named trans-(E) and 
cis-(Z), which may undergo isomerization upon exposure to 
ultraviolet radiation [46]. The 4-hydroxystilbene skeleton 
in resveratrol acts as an antioxidant pharmacophore 
with the ability to scavenge free radicals [47, 48]. Several 
studies focused on this antioxidant capacity showed that 
it inhibits both the formation of copper-catalyzed LDL 
oxidation [49], and the peroxidation of membrane lipids 
[50]. Additionally, it restricts the release of inflammatory 
mediators contributing to cardiovascular disease [51], 
prevents the formation and growth of multiple types of 
cancers even by topical application in a model of skin 
cancer [43, 52] and is neuroprotective [53]. In contrast, 
a few studies have reported negative effects, such as 
increased atherosclerosis [54] and DNA damage [55].
Most of the health-enhancing properties of resveratrol 
are mediated by inhibition of cyclooxygenases enzymes 
COX-1 and COX-2 [56], various cytochrome P450s [57], 
NADPH oxidase (the enzyme responsible for reactive 
oxygen species (ROS) production) [58], PKD (protein 
kinase D) [59], S6 kinase [60], the transcription factor 
AP-1 (activator protein 1), and activation of sirtuins 
(Figure 1A), an evolutionary conserved family of NAD+-
dependent (class III) histone/protein deacetylases 
with a wide range of biological functions [61]. Sirtuins 
deacetylate a plethora of substrates such as NF-κB, p53, 
PGC1α (peroxisome proliferator-activated receptor gamma 
coactivator 1α), FOXOs (forkhead box transcription factors) 
[62]. All these regulators influence the mitochondrial 
environment and metabolic diseases [63], and are actively 
involved in inflammation, carcinogenesis, lipolysis and 
other pathologies [64-66].
Besides the antioxidant effects of resveratrol 
described in humans, its ability to increase lifespan have 
been shown in vitro and in vivo in several eukaryotic 
model organisms [67]; in budding yeast this phenotype is 
thought to be mediated by overexpression of the enzyme 
Sir2 [68-70], which consumes NAD+ resembling lifespan 
extension by caloric restriction [71]. Homologs of this 
enzyme upregulated by resveratrol in worms [72], fruit 
flies [73], short-lived fishes [74-76], obese mice [43], and 
rhesus monkeys fed a high-fat/high-sucrose diet [77] are 
also reported to extend lifespan. Nevertheless, relevant 
experiments in worms and Drosophila have cast doubt on 
the robustness of the previously reported effects of sirtuins 
on lifespan control [78]. Mammalian SIRT1 is the most 
characterized of the seven sirtuins (SIRT1-7) and it regulates 
various cellular processes through the correct activation of 
AMPK and inhibition of mTOR signaling. SIRT1 is the main 
target of resveratrol in vivo (Figure 1A) through a direct 
allosteric binding that enhances deacetylation of non-
tagged peptide substrates [70, 79-81]. Its overexpression 
is beneficial in cellular models of Alzheimer’s disease 
[82], cancer [83], type II diabetes [84], and cardiovascular 
disease [66]. Despite all these positive data, healthy wild-
type mice show no increase in longevity by resveratrol 
treatment, and there are no large-scale studies on 
lifespan of healthy humans to date [42, 62]. Therefore, 
while data from the effects on mammalian lifespan in 
population studies is limited, it shows a remarkable 
capacity to enhance health and longevity in the presence 
of pathologies due to its pleiotropic effects, which exert 
physiological defence mechanisms that increase survival 
and make its pharmacological assessment complicated at 
the same time [85]. Nonetheless, it remains inconclusive 
whether resveratrol contains life-prolonging properties 
[86]. The large amount of on-going clinical trials in 
different pathological contexts and clinical settings is 
likely to produce valuable data of its effects on human 
health.
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Targeting the GH/IGF axis in aging 
and age-related diseases
Growth hormone (GH) or somatotropin secretion leads to 
a plethora of effects connected to cellular and organismal 
growth and is reduced during aging, a phenomenon 
known as somatopause [87]. In addition, mutations in 
the GH axis increase lifespan, while expression of bovine 
GH in mice reduces it [88]. These findings resulted in 
proposing and even misusing human GH as an anti-aging 
therapy (Figure 1A). The effects of such therapies are 
questionable: revisiting and analysis of clinical trials on 
GH supplementation in the elderly revealed minor benefits 
related to adipose tissue composition and an increased 
risk of insulin resistance development or diabetes mellitus 
in more than half of the male participants during 26 weeks 
of GH therapy [89, 90]. While systemic administration 
of GH is probably detrimental or even dangerous, local 
treatments might have beneficial effects: GH injections 
in the knee of older individuals showed improvements in 
tendon collagen synthesis [91].  
An interesting prospect in treatment of aging-
related diseases is the utilisation of GH antagonists or 
somatostatin analogues (Figure 1A) normally used in 
treatment of acromegaly. Acromegaly, caused by excess 
GH in humans, is manifested by increased growth of 
hands, feet, face and megalocardia [92]. Patients with 
acromegaly are often insulin-resistant, develop diabetes 
mellitus, have cardiovascular problems and have 
increased risk of colon cancer occurrence [93]. Treatment 
with somatostatin analogues that inhibit GH secretion or 
the GH antagonist pegvisomant (that inhibits endogenous 
GH binding to its GH receptor), effectively brings mortality 
rates of acromegaly patients to those of unaffected 
population [93]. Pegvisomant is more efficient compared 
to somatostatin analogues for normalising IGF-1 levels 
and, while the results of combinatorial therapies are very 
encouraging [94], a large a global safety surveillance study 
(ACROSTUDY) set in 14 countries (373 sites) has concluded 
that pegvisomant is safe and effective for patients with 
acromegaly as monotherapy [95].
IGF-1/insulin signaling is extensively studied in the 
context of lifespan in invertebrates, with a number of 
studies in murine models [96]. Notably, a recent study 
in mice showed that insulin-like growth factor-1 receptor 
(IGF-1R) monoclonal antibodies (mAb) are a promising 
anti-aging approach (Figure 1A): IGF-1R mAb preferentially 
improved female healthspan and increased median 
female lifespan by 9%. These changes were accompanied 
by a reduction in both cancer occurrence and general 
inflammation [97]. The best evidence of improved human 
healthspan for the IGF-1 pathway derives from studies on 
centenarians. These individuals are more likely to have 
IGF-1 receptor variants that are associated with reduced 
function. In addition, reduced IGF-1 levels are predictive of 
enhanced survival in female nonagenarians (i.e. women 
90-99 years of age) [98].
Metformin
Metformin is the most widely used oral hypoglycemic 
agent and a first-line treatment for non-insulin-dependent 
(type 2) diabetes [99]. This compound is derived from a 
natural product called galegine obtained from the plant 
French lilac Galega officinalis [100]. Extracts of this plant 
were used in herbal medicine in medieval times for the 
treatment of painful/frequent urination accompanying 
diabetes mellitus. The glucose-lowering activity of 
galegine was discovered in 1920s, proving to be toxic in 
humans, but was re-introduced to clinical use in 1957 
when was established as a safe and effective therapy for 
the treatment of type 2 diabetes [101]. Considering that 
this drug was not designed to target a specific pathway or 
disease and, despite its clinical use for over 60 years, the 
primary molecular mechanism of this dimethylbiguanide 
has remained unclear [99]. Several studies have 
established that the major effects of the compound are 
the suppression of ˃60% gluconeogenesis/lipogenesis in 
the liver and the increase in insulin-mediated uptake of 
glucose in muscles [102, 103]. These have been attributed 
to different pathways including AMPK (Figure 1A).
The adenosine monophosphate-activated protein 
kinase (AMPK) pathway is an evolutionarily conserved 
signaling pathway that senses cellular energy status through 
AMP/ATP and ADP/ATP ratios promoting catabolism and 
inhibiting anabolism [104]. It is not a surprise that dietary 
restriction activates AMPK and nutritional or caloric 
overload inhibits it, leading to increased occurrence of 
metabolic syndrome [105, 106]. AMPK modulates multiple 
processes such as gluconeogenesis, lipid oxidation, 
mitophagy and protein synthesis through TOR regulation 
[104]. AMP-activated protein serine/threonine kinases 
are heretotrimeric consisting of one enzymatic and 
two regulatory subunits. AMPK is tightly regulated by 
upstream kinases and phosphatases such as liver kinase B 
(LKB), Ca2+/calmodulin-dependent protein kinase kinase 
β (CaMKKβ) and transforming growth factor-β-activated 
kinase 1 (TAK1) [107-109]. Intense studies have provided 
insights on the structure and function of AMPK and how 
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small molecules can inhibit or enhance its actions [110, 
111]. 
AMPK is directly linked to aging. Beyond cellular 
energy status AMPK coordinates and controls repair and 
housekeeping mechanisms linked with maintenance, 
senescence and lifespan, such as autophagocytosis [112], 
ER stress suppression [113], oxidative stress alleviation 
[114] or suppression of inflammation [115]. Overexpression 
of AMPK can extend lifespan in worms [116] and Drosophila 
[117]. In mammals the situation is complicated, with gene 
deletions having severely detrimental effects [118]. AMPK 
activation through physical exercise has beneficial effects 
[119], while activation in pathological conditions such as 
stroke can enhance pathologies and induce additional 
cellular and tissue damage [120, 121]. The ability of AMPK 
to be activated upon certain stimuli declines during 
lifespan. For example, AMPK activity increases within 
muscles of young but not old rats [122]. Decline in the 
AMPK activation ability with aging is now linked with 
age-related diseases such as cardiovascular diseases and 
metabolic syndrome [123, 124]. As already mentioned, 
physiological regulation of AMPK through nutrition 
and exercise is possible. Nevertheless, increasing data 
strongly suggests potent activation of the pathway with 
the use of drugs, some of them as common as metformin 
and aspirin.
Metformin-mediated actions that are AMPK-
dependent involve phosphorylation/activation of AMPK 
in its catalytic α1/α2 subunits at threorine-172, mediated 
by LKB1 (liver kinase B1) [125]. This is triggered by 
the inhibition of the mitochondrial respiratory chain 
complex I, which produces a decrease in ATP levels 
together with an increase in the ratios of ADP/ATP [126] 
and AMP/ATP that activate AMPK [127]. The latter results 
leading in subsequent phosphorylation of CRTC2 (CREB-
regulated transcription coactivator 2) and CBP (CREB-
binding protein), that downregulate gluconeogenic gene 
expression [128, 129]. Interestingly, another study reported 
an AMPK-independent pathway based on results from 
AMPK α1/α2 knockout mice, indicating that the decrease 
in glucose production occurs through the regulation of 
gluconeogenesis flux in response to a decrease of the 
hepatic energy availability instead of direct suppression 
of gluconeogenic gene expression [130]. 
Lifespan extension is among the therapeutic 
opportunities being explored for metformin. They have 
been attributed to transcription, genome stability, 
epigenome marking, metal-interactive regulation of protein 
function that inhibit pro-inflammatory proteases and anti-
apoptotic pathways independent of its glucose reducing 
effects [131-134]. This was proved in various systems 
including S. cerevisiae where extension of chronological 
lifespan was reported due to glycation inhibition (mimics 
calorie restriction) restoring deregulated proteins involved 
in mitochondrial respiration and facilitating the shift of 
metabolism from fermentation to respiration [135]. In C. 
elegans metformin works via impairment of folate and 
methionine metabolism in the intestinal microbiome 
[136], while in mice reduces adipose tissue inflammation 
[137]. Within fly intestinal stem cells, metformin inhibits 
aging phenotypes in an Atg6 (autophagy-related 
6)-dependent manner [138]. Additionally, metformin 
is reported to inhibit differentiation of monocytes into 
macrophages through disruption of NF-κB (nuclear factor 
kappa-light-chain-enhancer of activated B cells) signaling 
[139]. In human plasma it suppresses proinflammatory 
cytokines such as CCL11 (CC motif chemokine 11) involved 
in age-related cellular and tissue dysfunction and affects 
the neutrophil to lymphocyte ratio, which is a marker of 
inflammation linked to mortality [140]. 
Clinical trials in humans confirmed the significant 
reduction of CRP (C-reactive protein) levels, which is a 
marker of systemic inflammation. Interestingly, such an 
effect is not observed with resveratrol treatment [99]. 
In cells derived from patients with Hutchinson-Gilford 
progeria syndrome, metformin lowers progerin production 
(a toxic protein also present in normal subjects at lower 
levels). This is done through inhibition of SRSF1 (serine-
arginine rich splicing factor 1) alleviating pathological 
defects. In this scenario, cellular stress-induced AMPK 
activation promotes both the activity of the splicing factor-
associated protein p32. This protein acts as endogenous 
inhibitor of SRSF1 and binds to mitochondrial mRNAs in 
vivo, regulating their efficient translation. As these RNAs 
code for proteins involved in oxidative phosphorylation, 
p32 is pivotal in maintaining this essential cellular 
function. In addition, p32 affects the transcriptional 
activity of NFE2L2 (Nuclear factor erythroid-derived 2-like 
2), a main regulator of the antioxidant response disrupted 
in progeria cells [134]. Another possibility to explain the 
health span-extension effects of metformin is through 
the inhibition of nutrient/energy-sensing metabolic 
pathways such as the insulin/IGF-1 (insulin-like growth 
factor 1) and mTOR  [133, 141]. Other studies have reported 
neuroprotective effects against cognitive dysfunction by 
hippocampal neurogenesis/differentiation and inhibition 
of aging-related neuroinflammation in mice [142-144]. The 
overall favourable effects of metformin in physiological 
functions through multiple modest, but substantial, 
effects, combined with its well-characterized profile, 
suggest that it may be beneficial for the treatment of 
normal or pathological aging [134].
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Aspirin
Acetylsalicylic acid is the most common nonsteroidal 
anti-inflammatory drug and globally used medication. 
Considered against its potential side effects of producing 
stomach ulcers and bleeding, is currently widely used 
for the treatment of pain, fever, inflammation, platelet 
aggregation, prevention of cardiovascular pathologies 
and cancer [145]. Its active component salicylate is 
chemically synthesized from the bark of the willow tree 
Salix alba. Its therapeutic use dates back to ancient times 
but pure acetyl salicylate has been manufactured and 
commercialized since 1899 [146, 147].
Aspirin affects multiple signal transduction 
pathways; the principal mode of action discovered in 
1971 is through the irreversible inactivation of COX-1 
(prostaglandin-endoperoxide synthase, PTGS1) and the 
inhibition of COX-2 (PTGS2), suppressing prostanoid 
biosynthesis [148] (Figure 1B). The drug is rapidly broken 
down in vivo to salicylate. The latter has multiple effects 
such as uncoupling oxidative respiration through proton 
transport on the inner mitochondrial membrane [149]; 
acetylation and inhibition of G6PD (glucose-6-phosphate 
dehydrogenase), which catalyzes the first reaction in the 
pentose phosphate pathway involved in the regulation 
of oxidative stress [150]; activation of AMPK via Thr-172 
phosphorylation; and activation of protein kinase 
IKKβ (inhibitor of nuclear factor kappa-B) that arrests 
the pro-inflammatory transcription factor NF-κB [151]. 
Additionally, salicylate competitively inhibits the binding 
of acetyl coenzyme A (the sole acetyl group donor) 
to acetyltransferases such as EP300 (E1A-associated 
protein p300) thus inhibiting its activity and inducing 
the autophagic cascade that enhances longevity, still 
observed in the absence of AMPK [152, 153]. 
The pro-health benefits of aspirin also include the 
delay in the onset of various age-related diseases and an 
increase in the maximum and mean lifespan of different 
organisms through pleiotropic molecular mechanisms 
[154]. Lifespan extension have been reported in worms 
via attenuation of endogenous levels of ROS as well as 
upregulation of antioxidant genes [155], activation of the 
transcription factors DAF-12 and DAF-16 that increase lipid 
hydrolysis and inhibit the proliferation of germline stem 
cells without alterations in the number of offspring [154]. 
In the fruit fly, it has been associated to a decrease in 
female fecundity produced by the inhibition of the heme 
peroxidase Pxt, a COX-like facilitator of follicle maturation 
[156]. These effects are accompanied by increased 
resistance to stress and improved locomotor activity that 
are overall mediated by the Pkh2-ypk1-lem3-tat2 signaling 
pathway [157]. Interestingly, in mice, aspirin increases 
the survival of males but not females [158]. Different 
trials have shown protective effects against Alzheimer’s 
and Parkinson’s disease, low risk of cancer incidence 
and mortality[159, 160] with metabolic and immunity 
functions [154]. However, the successful use of aspirin in 
humans to actually increase healthspan and lifespan has 
yet to be tested [161]. 
Future prospects
The current challenges for the treatment of multiple 
age-related diseases are focused on the identification of 
molecules that could increase human lifespan and the 
development of strategies to safely assess them in the 
population. The common mechanisms of action observed 
between aspirin, resveratrol and metformin could bring 
light to this matter by pharmacologically inducing the 
benefits of caloric restriction. Statins are inhibitors of the 
HMG-CoA-competitive reductase and exhibit a plethora 
of effects. They affect cholesterol production and protein 
prenylation resulting in improvement of endothelial 
and immune function as well as in other cardiovascular 
benefits [162]. Despite the heterogeneity and inconclusive 
results from clinical trials, statins present some potential 
in terms of their anti-inflammatory properties and in the 
possibility of enhancing or improving present therapies 
for some types of cancer [162].
Angiotensin-converting-enzyme (ACE) inhibitors and 
angiotensin II receptor blockers are used for hypertension 
treatment. Nevertheless, Angiotensin II is shown to be 
implicated in age-related cardiovascular disease in rats 
[163]. The renin-angiotensin system is shown to play an 
important role in aging kidneys [164], while angiotensin II 
inhibitors increase the lifespan of hypertensive rats [165, 
166]. In humans, there is no large study for the effects on 
lifespan and aging rates. However, beneficial effects on 
cardiac hypertrophy [163] and lower incidence of cancer 
[167] are very promising. 
Recent data has shown that the Ras-Erk-ETS pathway 
is a drug target of longevity [168] with trametinib, a 
specific inhibitor of the Ras pathway being able to extend 
lifespan via adult-onset administration [168] in the fruitfly. 
The ETS transcriptional repressor, Anterior open (Aop) is 
central to the lifespan extension downstream of reduced 
insulin/IGF-1 signaling or Ras attenuation [168]. The Ras 
pathway is highly conserved and these data show promise 
for anti-aging targets in humans. Finally, inhibition of the 
TORC1-regulated RNA Polymerase III, an essential enzyme 
responsible for transcribing tRNAs and 5S ribosomal RNA, 
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extends lifespan in yeast, worms and fruitfly [169]. Pol III 
inhibition within adult worm or fly guts is sufficient to 
extend lifespan and results in amelioration of age-related 
gut deterioration and pathology. These results, place Pol 
III as an interesting potential target for pharmacological 
interventions. 
Dietary restriction, activation of AMPK through 
metformin and inhibition of TOR through rapamycin 
and Torins lead to increase in autophagy. Autophagy is 
a degradation pathway leading to recycling of cellular 
material and removal of damaged macromolecules and 
organelles that may pose a burden to the cell. Autophagy 
plays a crucial role in cellular homeostasis, development, 
immunity, tumour suppression and cellular metabolism, 
prevention of neurodegeneration and lifespan extension. 
Therefore, pharmacological stimulation of autophagy may 
be an effective approach for preventing or ameliorating 
certain human diseases and reducing aging symptoms. 
Towards identifying new autophagy inducers, high-
throughput screens with chemical compound libraries 
containing around 300,000 compounds are utilised. 
In a recent screen three candidate molecules have been 
identified that may be clinically useful as autophagy-
inducing agents [170]. Interestingly, a cell-based 
quantitative high-throughput image screening (qHTS) 
for autophagy modulators using mouse embryonic 
fibroblasts (MEFs) has identified (apart from a number of 
novel autophagy inducers, inhibitors, and modulators) a 
group of compounds related to dopamine receptors. These 
compounds are commonly used as clinical psychiatric 
drugs. These include indatraline hydrochloride (IND), a 
dopamine inhibitor, and chlorpromazine hydrochloride 
(CPZ) and fluphenazine dihydrochloride (FPZ), two 
dopamine receptor antagonists. FPZ-induced autophagy 
happens through mTOR inhibition but IND and CPZ can 
induce autophagy via a TOR-independent manner [171]. 
These results underline once again the importance of 
revisiting and repurposing already tested and trialled 
drugs in biogerontology. Further studies on the same 
theme focus on natural products [172].
While intense biogerontology research is focused on 
genetic factors it is now evident that epigenetic regulators 
impact greatly on lifespan. Increasing evidence shows that 
histone deacetylase (HDAC) inhibitors, able to reverse the 
deacetylation of histone tails and activate the expression 
of particular genes, are a promising class of anti-aging 
compounds that can play major roles for combating age-
related diseases [173]. HDAC inhibitors have lifespan-
extending effects to preclinical animal models such 
as fruitflies, C. elegans and rodents [173]. Importantly, 
preclinical and clinical studies using HDAC inhibitors 
for age-related conditions have generated very positive 
outcomes: a wide range of these molecules have emerged 
as anticancer drugs [174]. A number of them are already 
approved for specific lymphomas and haematological 
cancers while others are currently on different stages of 
clinical development and trials [175, 176].  HDAC inhibitors 
have also been shown to be beneficial in the contexts of 
neurodegenerative disease, metabolic and cardiovascular 
problems as well as inflammatory conditions [173]. 
Organismal aging has a cellular component and can 
be viewed as the combination of limited chronological 
and replicative lifespan of the cells that the organism is 
composed of. While chronological lifespan is defined 
as the time that a postmitotic population is viable, 
replicative lifespan is the number of mitotic divisions that 
a mother cell can give rise to until senescence. Cellular 
senescence, first described by Hayflick and Moorhead 
in the 1960s, is directly linked with decreased telomere 
length and decreased telomerase activity. During aging 
and exposure to various intra- and extracellular stresses a 
rise in senescent cells is observed. If senescent cells are not 
removed, the senescence state is induced in neighbouring 
young cells leading to tissue dysfunction [177]. Telomerase 
activator therapies are currently undergoing with at 
least one product, TA-65, already available. TA-65 is 
able to increase telomerase levels and healthspan in 
mice. Nevertheless, mean and maximal lifespan was 
not increased [178]. TA-65 has also been reported to 
decrease senescent immune system cells in patients 
[179]. Telomerase-based interventions although not fully 
understood will have no effects on the chronological 
lifespan of cells within the body (such as postmitotic brain 
cells). In addition, as telomerase favours tumorigenesis, 
its long-term efficiency and safety as anti-aging therapy is 
still questionable [177]. 
An area of intense interest in drugs with rejuvenating 
potential related to senescent cells is senolytics. Senolytic 
drugs (term originating from ‘senescence’ and ‘lysis’) 
selectively destroy senescent cells from tissues leading 
to improved health markers in mouse models. The first 
molecules to be identified as senolytics in 2015 were 
Dasatinib and Quercetin. Dasatinib, a small molecule 
targeting BCR/Abl (the Philadelphia chromosome), 
Src, c-Kit, ephrin receptors, and several other tyrosine 
kinases. Dasatinib is sold under the brand name Sprycel 
and is a chemotherapy medication used to treat certain 
cases of chronic myelogenous leukemia (CML) and acute 
lymphoblastic leukemia (ALL). Quercetin is a plant 
flavonol from the group of polyphenols and is found in 
fruit, vegetables, leaves, and grains. Dasatinib is able to 
eliminate senescent human fat cell progenitors, while 
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quercetin is more effective against senescent human 
endothelial cells. The combination of Dasatinib and 
Quercetin is effective in eliminating senescent mouse 
embryonic fibroblasts. Combinations of Dasatinib and 
Quercetin are shown to reduce senescent cells in aged, and 
progeroid mice [180]. Navitoclax (ABT-263) was the third 
senolytic to be identified [181]. Navitoclax is a protein–
protein interaction inhibitor targeting the BCL-2 family 
of apoptotic proteins. The finding that BCL-2 inhibitors 
can act as senolytics helped towards the identification of 
analogues A1331852, A1155463 and ABT-737 that inhibit 
BCL-2 family members, as senolytics [182]. In addition, 
the action of the flavonol fisetin and the alkaloid 
piperlongumine as senolytics or senotherapeutics is 
now established [182-184]. A FOXO4 peptide able to 
perturb the FOXO4 interaction with p53 was identified 
[185]. In senescent cells, this selectively causes p53 
nuclear exclusion and cell-intrinsic apoptosis. Under 
conditions where it was well tolerated in vivo, this FOXO4 
peptide neutralized doxorubicin-induced chemotoxicity. 
Moreover, it restored fitness, fur density, and renal 
function in both fast aging and naturally aged mice [185]. 
This is an exciting focus in biogerontology studies with 
new data amounting on the beneficial effects of senolytics. 
Nevertheless, their effects on young tissues are not quite 
clear yet [186]. A characteristic of this research is again the 
repurposing of known and trialled drugs.  
It is more than evident that the field rapidly progresses 
through the identification of lifespan-increasing genetic 
and environmental factors. However, the need now is the 
identification of those interventions that increase human 
healthspan while not enhancing morbidity periods 
through clinical trials. Focused drug design studies as 
well as pre-clinical and clinical trials are of essence to 
realise the treatments that could delay and ameliorate or 
even prevent age-related ailments (Table 1).      
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